Introduction
Effective therapy for Alzheimer's disease (AD) is a major unmet medical need. The major demographic risk for development of AD is age with risk doubling approximately every 5 years after age 65 such that by the age of 85, one's chances of having dementia due to AD ranges from 25%-40%. Therefore, the prevalence of AD is expected to double every 20 years, largely because of an anticipated increase in the average expected life span. Based on estimates that 35 million people worldwide have AD today, it is predicted that well over 100 million individuals will have AD in 2050 (Alzheimer's Association, 2010; Wimo et al., 2010) . If nothing is done, the personal, economic, and societal toll of the ongoing and growing AD epidemic will be immense.
Although key aspects of AD pathogenesis remain enigmatic, scientific advances over the last 25 years have provided sound rationale for the development of potentially disease-modifying AD therapies (Golde, 2005; Selkoe, 2001) . These therapies primarily target the suspected trigger(s) of the disease. Therapies that have advanced the farthest have primarily been developed based on the proposed initiating role of amyloid b-protein (Ab) aggregates (Golde et al., 2010) . These therapeutic advances, coupled with advances in early detection of ADrelated pathology in nondemented individuals, suggest that concerted translational research efforts focusing on prevention or early intervention could dramatically reduce the incidence and prevalence of AD. However, current trial design involves treatment of symptomatic patients, a setting where failure to show efficacy may be even more likely given the disease progression. Misalignments of the rationale for the therapy, its preclinical testing, and the actual testing of the therapy in human AD clinical trials have resulted in barriers to effective drug development that we must recognize and that will be very challenging to solve. This perspective will focus on how this dilemma in AD translational research has evolved. We begin by summarizing both the current state of AD therapeutic development and the paradigm shift that is occurring with respect to being able to detect and track underlying AD-related pathologies in humans in the absence of significant cognitive impairment, as both of these issues are critical to how the dilemma has arisen and how we might solve it. We next focus on the core issue of the mismatch between the design of preclinical studies that evaluate potential AD therapies and the current translation of those therapies to human clinical trials. We conclude with a discussion of the main obstacles that must be overcome to solve this dilemma and create the desired paradigm shift in translational AD research.
The Current State of AD Therapeutics and Therapeutic Discovery For the typical AD patient, current symptomatic therapies (acetylcholinesterase inhibitors and memantine), demonstrate only minimal to modest symptomatic benefit that is not sustained. Moreover, there is virtually no evidence that either of these types of treatments significantly alter disease progression (Schneider et al., 2011) . Although there is renewed effort to develop novel cognitive enhancing agents that target different pathways, only one of these, a repurposed drug, dimebon (Doody et al., 2008) , has entered phase 3 efficacy studies in humans. Results from the first phase 3 study designed to confirm promising phase 2 results, unfortunately, showed no evidence of efficacy (Jones, 2010) .
A large percentage of current therapeutic development in AD is focused on therapies that target the Ab peptide or Ab aggregates (Golde et al., 2010) . Accumulation of fibrillar Ab aggregates in senile plaques within the brain parenchyma is one of the classic pathological hallmarks of AD. A detailed understanding of the proteolytic processing that releases Ab from the amyloid precursor protein (APP) and its subsequent aggregation in the brain has provided a number of approaches to what may be generically referred to as anti-Ab therapy. To date, four general categories of anti-Ab therapy have been developed: (1) agents that decrease or modulate Ab production in a manner that is designed to prevent or slow Ab aggregation and accumulation, (2) therapies that degrade or enhance clearance of Ab aggregates, (3) therapies designed to block Ab aggregates, and (4) therapies designed to neutralize toxic Ab aggregates.
The rationale for these anti-Ab therapies has been validated in preclinical models over the last 20 years and is rooted in the amyloid cascade hypothesis of AD (Hardy and Selkoe, 2002; Hardy and Higgins, 1992) . This hypothesis posits that accumulation of Ab aggregates in the brain triggers a complex neurodegenerative cascade, which results in progressive cognitive impairment and dementia. Though the original amyloid hypothesis has been expanded to encompass the likely possibility that multiple different types of Ab aggregates (intracellular aggregates, oligomers, fibrils, and protofibrils) contribute to the cascade (Walsh and Selkoe, 2004) , the essential tenants of this hypothesis remain the same. The main support for the hypothesis has come from a convergence of genetic, cell biological, animal modeling, pathological, and biophysical studies. Collectively, these studies demonstrate a primary effect of genetic alterations that cause familial forms of AD is to alter Ab production or Ab itself in a way that promotes its aggregation and accumulation in the brain (Selkoe, 2001) . Additional indirect support for the hypothesis has come from studies of other central nervous system (CNS) proteinopathies (Forman et al., 2004; Ross and Poirier, 2004) . A common theme in many neurodegenerative diseases is that genetic mutations, overexpression (often due to gene duplication), ineffective removal, or age-associated changes result in accumulation of alternatively folded protein aggregates that sequentially trigger a degenerative cascade, neuronal demise, and ultimately regional or widespread brain organ failure. In this regard, the British and Danish familial dementias are notable with respect to the parallels with AD in both clinical and pathological features and hypothesized mechanism (Ghiso et al., 2006) . The key difference between these two familial dementias and AD is that the trigger for the former appears to be accumulation of different mutant amyloidogenic peptides derived from the BRI2 (ITM2B) protein versus the Ab peptide.
The Ab Aggregate Hypothesis Is Reflected by Biomarker Studies in Humans Recent biomarker and imaging studies in living humans, along with classic postmortem studies from Braak and Braak (1997) , the Religious Order Study, and other human studies (Bennett, 2006; Blennow, 2004; Jack et al., 2009; Morris and Price, 2001; Perrin et al., 2009; Shaw et al., 2009) , have begun to frame a theoretical average timeline for the development of various pathological features that characterize AD and the relationship to initial diagnosis of dementia or prodromal dementia (i.e., mild cognitive impairment due to AD). Cross-sectional and ongoing longitudinal biomarker studies reveal that the diagnosis of AD occurs after a relatively long prodromal clinical phase, which by itself requires the presence of a dementia syndrome manifested by cognitive impairment that interferes with many aspects of daily function.
Although the human AD biomarker and imaging cascade is sure to be refined and advanced, the current data strongly support the following hypothetical scenario. First, in normal elderly individuals destined to develop AD, Ab aggregate accumulation begins in the brain ten or more years before the onset of dementia as a result of reduced clearance or increased production. As the Ab pathology progresses, clinical correlates of Ab accumulation, such as amyloid plaques visualized by radioligand imaging or low cerebrospinal fluid (CSF) Ab42 concentrations possibly due to sequestration in the brain can be detected. Within an estimated timeline of 10-15 years, Ab accumulates to levels that are present in brains of AD individuals. Accumulation of Ab may plateau, though these observations are based on cohort studies and ongoing longitudinal amyloid imaging studies will be needed to validate both the time course and the kinetics of accumulation. During this protracted phase of progressive Ab accumulation in brain, a number of poorly understood cellular changes take place reflecting increasing neuronal injury. For example, there is an increase in CSF total tau and phosphorylated tau levels that probably reflects synaptic loss and neuronal demise in brain parenchyma. Coincident or shortly after tau CSF levels rise, structural magnetic resonance imaging (MRI) can reveal regional brain atrophy, and functional MRI can show evidence for altered network activity between brain regions. Cognitive function and instrumental activities of daily living may deteriorate but generally still fall within a normal range. More commonly, subtle memory impairments might be detected, with more severe cognitive changes and overt dementia occurring later. This concept that very early, prodromal AD and mild cognitive impairment phases can be detected years before dementia becomes apparent has led to two workgroups proposing new guidelines that put the clinical evolution of AD on a continuum that starts with a preclinical phase during which the Ab pathology of AD can be detected, followed by evidence of neurodegeneration, both without any clinical findings, followed by the earliest clinical signs (Dubois et al., 2010) (http://www. alz.org/research/diagnostic_criteria; Figure 1 ).
The remarkable parallels between the hypothesized cascade, experimental evidence from animal models, and measurable biological events occurring in humans, reinforce the rationale for anti-Ab therapeutics. However, the cascade hypothesis only predicts that if Ab accumulation in the brain is attenuated or prevented, then so too will be the subsequent development of AD. It remains an open question whether targeting Ab aggregates at any stage in the pathological process will result in clinically effective therapeutics. For example, intervention with an anti-Ab therapy in the disease state with longstanding amyloid deposited in plaques, substantial synaptic loss and neurodegeneration, and manifest clinical symptoms may be completely ineffective. Even fairly early intervention in nondemented individuals ( Figure 1 , stage 2) in which the neurodegenerative disease process has started may be ineffective. It is possible the degenerative changes will continue regardless of whether the therapeutic agent decreases Ab production or even clears Ab deposits from the brain. In general, given the reasonable possibility that some aspects of the neurodegenerative cascade may be self-reinforcing, become independent of the initial trigger, or are irreversible in nature, one might predict that anti-Ab therapies will be increasingly ineffective in terms of attenuating the course of illness as the underlying pathology progresses and clinical symptoms emerge. Ultimately, the true test of the cascade hypothesis is to conduct a true primary prevention trial with anti-Ab therapy in patients destined to develop AD but prior to the onset of measureable Ab deposition. Alternatively, one might envision that the hypothesis could be reasonably well tested in secondary prevention (very early intervention) trial in subjects with Ab pathology only, prior to the neurodegenerative phase (preclinical stage 1). In the later scenario, the test potentially would be more effective if the therapeutic modality enhanced clearance of Ab.
Critiques of the Ab Aggregate Hypothesis
In order to conduct a primary prevention study with a therapeutic agent for any disease, one needs a strong scientific rationale. Although the Ab aggregate/amyloid hypothesis is not without its critics, it has very strong scientific underpinnings. In the context of trying to move the field toward primary prevention studies with anti-Ab therapies, it is important to consider the views of those who are skeptical about the role of Ab in AD. One valid critique of the hypothesis is that most of the experimental evidence supporting the hypothesis comes from the study of the genetic alterations that cause familial autosomal dominant AD (Selkoe, 2001; Younkin, 1998) . Thus, a key assumption is that pathological cascades in sporadic AD are the same as in familial AD. Given that the typical genetic and sporadic forms of AD are very similar with respect to postmortem findings, clinical course, and evidence from the emerging biomarker and imaging cascade in sporadic AD, this seems a reasonable assumption (Shepherd et al., 2009) . Indeed, when examples from other human diseases with genetic and sporadic forms, such as hypercholesterolemia and prion diseases, are considered, this concept is quite tenable (Brown and Goldstein, 1986; Prusiner, 1998) . Nevertheless, because of the late age of onset, sporadic AD is not a completely uniform clinical or pathological entity: it is complicated by other systemic or CNS illnesses and conditions, and the biological processes of aging. Thus, the underlying brain pathology that results in clinical dementia may represent the convergence of independent processes and not necessarily a single pathologic entity (Small and Duff, 2008) , as thought to be the case in early onset familial AD. Indeed, in the over-80-year-old population who have died with a clinical diagnosis of probable AD dementia, postmortem phenotypes often show not only plaques and tangles pathology characteristic of AD, but other proteinopathies and vascular insults as well (Dickson, 2001) . However, even if this is the case, and multiple pathologies synergize in some subpopulations of those affected with what we define as AD, one might still predict that preventing Ab deposition would have substantial, but perhaps not complete, efficacy.
Another critique of the Ab cascade hypothesis arises from the imperfect correlation between cognitive status and Ab deposits in the brain, and the postmortem findings of significant Ab accumulation in the brains of elderly who were cognitively intact shortly before death Giannakopoulos et al., 2003; Nä slund et al., 2000) . The criticism that follows is Ab deposition itself does not necessarily predict or cause clinical AD. Such observations, however, can be understood in several other ways. First, there may be a threshold effect that involves the density and duration, or even rate of Ab accumulation that together with the age of onset of the pathological processes determines the onset of the clinical manifestations of AD. Second, as with other illnesses, there are almost certainly genetic, pathological, epigenetic, and environmental mediators that modulate progression, disease course, and manifestation of illness. For example, one proposed mediator involves the concept of ''cognitive reserve' that hypothesizes that factors that enhance neuroplasticity and synaptogenesis, may make an individual more resistant to the clinical manifestations of the underlying neuropathology, thereby delaying onset of the clinical expression of the illness (Cummings et al., 1998; Stern et al., 1999) . Third, it is also possible that early subtle cognitive impairment of AD that we might now refer to as preclinical stage 3 is often not recognized in elderly people who die and come to autopsy. Some evidence for this is from the Religious Order Study where those who died without cognitive impairment and who had intermediate or high likelihood of AD based on neuropathological examination scored 0.25 standard deviation lower on episodic memory tests than those without pathology , worsening of episodic memory being the earliest and most characteristic cognitive phenotype for AD (Dubois and Albert, 2004) .
Finally, it has become common to explain the results from failed AD therapeutic trials with presumptive anti-Ab therapies as evidence that the hypothesis is wrong. This is clearly inaccurate, as to date, such trials were not definitive tests of the cascade hypothesis, but rather expedient ways to test potentially disease-modifying AD therapeutics in the current clinical, regulatory, and fiscal environment. None of the putative antiAb agents that have failed in pivotal phase 3 therapeutic trials were optimal or even optimized agents within their class of anti-Ab therapeutics: Alzhemed (tramiprosate, homotaurine) was a weak aggregation inhibitor; Flurizan (tarenflurbil, R-flurbiprofen) was a g-secretase modulator with low potency and poor brain penetration; and semagacestat, a nonselective g-secretase inhibitor (GSI), had significant mechanism-based toxicity limiting its dosage and efficacy with respect to lowering Ab production (Golde et al., 2010) . None of these drugs showed efficacy against primary endpoints in phase 2 trials but were advanced to phase 3 nonetheless.
Other anti-Ab therapies (e.g., Notch-sparing GSIs, humanized anti-Ab monoclonal antibodies, and second generation Ab vaccines) currently in therapeutic trials for AD are more likely to have improved effects on their respective targets, but it is unclear whether this will translate to clinical efficacy. These ongoing and planned trials should provide an answer to the questions raised above as to whether targeting Ab in symptomatic AD patients will have any efficacy at all. However, available phase 2 data would suggest if these compounds are going to have diseasemodifying effects and improve the course of cognitive decline in this patient population, the effect is going to be quite modest.
Other Therapeutic Approaches
Although most therapeutic activity in AD with respect to potentially disease-modifying therapy has focused on anti-Ab therapies designed to decrease Ab production or aggregate formation or remove preexisting aggregates, both tau-targeted and more general neuroprotective agents among others are also being developed (Golde et al., 2010; Salloway et al., 2008) . Development of anti-tau therapies has been hindered by a lack of clear insight into what is the optimal desired effect on tau (e.g., decreasing phosphorylation, blocking proteolysis, or preventing aggregation). Though animal modeling studies do provide evidence that Ab aggregates promote some aspects of tau pathology (Gö tz et al., 2001; Lewis et al., 2001 ), the precise mechanistic links between Ab and tau pathologies have not been established, thus hindering not only our ability to appreciate the biological connection but also to develop better animal models and identify druggable therapeutic targets.
Neuroprotective strategies are rational approaches but have generally not gained much traction with little progress in terms of new investigational drugs for AD (Salloway et al., 2008) . The reasons for this may stem from (1) a lack of understanding regarding the mechanisms of neural injury, (2) uncertainty regarding the best targets for neuroprotection in AD, (3) the inadequacy of current animal models as exemplified by the relative paucity of neurodegeneration in transgenic mice that are primarily models of amyloid deposition and do not exhibit the full spectrum of AD pathologies, or (4) the poor track record of successful translation of neuroprotective drugs from the preclinical to clinical phase in other neurological disease such as stroke or any neurodegenerative condition.
In any case, if one assumes the temporal sequencing in the Ab aggregate cascade is correct, then one would predict that antitau therapy will be most effective in the very early pathological phases of the disease and not after the stage when robust Ab deposition, synaptic loss, and neurofibrillary changes have begun. In contrast, general or focused neuroprotective strategies might be efficacious even in such later stages, as there is evidence for continued neuronal demise as the clinical dementia worsens.
The Treatment versus Prevention Dilemma
The preceding overview of the status of AD therapeutics highlights what can be referred to succinctly as the treatment versus prevention dilemma. Of primary importance is the point that anti-Ab therapy is most likely to show efficacy in a primary prevention setting. Certain therapeutic modalities that can result in Ab clearance could also show efficacy in Ab deposition stages of AD. However, current clinical trials designs have involved treatment of patients with AD dementia or mild cognitive impairment over generally 18 month to 4 year intervals (Schneider and Sano, 2009) . In these instances, one might predict that the likely outcome of anti-Ab therapy will be no observable beneficial clinical effect. Testing anti-Ab therapy in patients with clinically diagnosed AD may be analogous to treating a patient with atherosclerosis, myocardial infarctions, and heart failure with a cholesterol-lowering agent and expecting his current cardiac function and subsequent clinical course would noticeably improve. In such a setting, targeting the trigger of disease, or the pathophysiologic process that is protracted, is not likely to demonstrate efficacy. Indeed, one can speculate that if the early trial designs for the testing of statins were in patients in complete cardiac failure and used morbidity and mortality endpoints (as opposed to plasma cholesterol lowering), it is likely that statins would have failed to show efficacy. Though statins clearly lower cholesterol, even today it is challenging to demonstrate that statin treatment has significant impact on cardiovascular morbidity and mortality in nonselected patient populations.
Not only does the amyloid cascade hypothesis provide support for initiation of primary prevention or possibly very early intervention (secondary prevention trials) with anti-Ab therapy, but preclinical studies in Ab-depositing transgenic mouse models do as well (Ashe and Zahs, 2010) . The vast majority of preclinical studies in APP transgenic mice that show efficacy are equivalent to primary or secondary prevention, as treatment is typically begun either before the onset of amyloid pathology or in mice with very modest Ab loads. Even very old APP/Ab mouse models only appear to be good models of preclinical AD because they show amyloid deposition, amyloid-associated neuritic dystrophy, and plaque associated micro-and astrogliosis (Price and Sisodia, 1998) but typically no neurodegenerative phenotypes and minimal tau pathology. Thus, any study at any age in these mice mainly reflects likely outcomes in early preclinical stages of AD. Although many models do show cognitive impairments that can be interpreted to be reminiscent of AD in that they involve memory systems, the cognitive changes and their relationship to other pathological features vary from model to model, have inconsistent relationships with amyloid and other pathologies, and can often be rapidly reversed (Ashe, 2001) . Lastly, treatments given to APP transgenic mice when amyloid deposition and associated pathology are established are generally less effective (Abramowski et al., 2008; Das et al., 2001) . Thus, it is uncertain whether efficacy with respect to alleviating the behavioral changes observed in such mouse models, especially performed in preplaque stages, would be able to predict efficacy with respect to behavioral alterations in humans with symptomatic AD.
Recognizing and Overcoming the Medical and Scientific Obstacles to Solving the Treatment versus Prevention Dilemma
There are two straightforward ways to solve the dilemma through medical and scientific progress. First, with anti-Ab therapies and perhaps anti-tau therapies, we should conduct primary prevention or intervention trials in minimally affected individuals (secondary prevention in stage 1/2). A second, alternative, strategy would be to develop therapies more likely to work in symptomatic patients (i.e., in a preclinical stage 3 or prodromal AD).
When considering primary prevention or very early intervention in asymptomatic subjects, the key scientific issue will be whether a therapy can be developed that hits the target sufficiently to have a very good chance for disease modification and is sufficiently safe for use in people included in the trial but not destined to develop AD or likely to develop the clinically symptomatic illness only after several years of good health. Whether a candidate drug can be considered sufficiently safe will depend on (1) the underlying biology of the target (mechanism-based toxicity), (2) the ability to avoid off-target effects, and (3) an empirically determined assessment of benefit versus liabilities. Whether a therapy is safe enough will also be influenced by the conditions of use, whether one is considering a true primary prevention trial, a trial in preclinical AD, or a trial in established symptomatic AD, as the risk to benefit profile will shift toward tolerating greater risk with advancing clinical disease. In the later populations, the bar for safe enough is lower given the evidence for irreversible though protracted progression.
Many current anti-Ab therapeutic modalities fail the safe enough test even in symptomatic patients, especially given the long-term treatment that is necessary in this chronic condition. However, a number of modalities, such as selective g-secretase inhibitors, g-secretase modulators, and second or third generation vaccines, theoretically hold some promise for meeting the safe enough requirement for testing as prophylactic agent (Golde et al., 2010) .
From a medical perspective, a key issue will be whether the community will accept the concept of presymptomatic AD, which, to reiterate, is the presence of Ab aggregate accumulation with or without some evidence for neurodegeneration in the absence of detectible cognitive symptoms. This diagnostic construct is invaluable when considering moving toward primary prevention or early intervention trials as it potentially identifies the earliest manifestation of the disease. As noted previously, preclinical AD may exist for a decade or more before what has been referred to as prodromal AD or mild cognitive impairment due to AD, providing a window of opportunity for intervention. Preclinical AD also represents the boundary condition between two important therapeutic approaches: the true primary prevention of illness and the so-called 'secondary prevention' or treatment of the very earliest manifestations of illness. Future trials will need to account for and distinguish between the truly asymptomatic and preclinical AD.
Although we have seen remarkable and rapid advances in the ability to diagnose preclinical AD (Weiner et al., 2010) , in order to move toward primary prevention we need to advance our ability to predict who is at very high risk for AD and in what time frame they might develop observable pathology and subsequently clinical symptoms. Based on current data, we know that APOE 34 genotype, low CSF Ab42, and increased PET amyloid tracer binding in the brain, all confer substantially increased risk for the progression of preclinical AD to mild cognitive impairment (MCI) and MCI to AD (Blennow, 2004; De Meyer et al., 2010; Romas et al., 1999; Storandt et al., 2009) . But these markers do not provide information regarding onset of pathology. Even the presence of an APOE 34 genotype only indicates increased risk or earlier age-of-onset but fails to provide precise information with respect to timing of disease onset. Identification of additional factors that predict more precisely the risk for development of AD, what are generically referred to as premorbid biomarkers, could be very useful in identifying an at-risk population for a primary prevention study. Again, if we make an analogy to atherosclerotic disease, plasma cholesterol-testing serves as such a premorbid biomarker.
Given this reality, there is substantial interest in the field to test preventive agents in genetic forms of AD where large kindreds, such as one in Antioquia, Colombia, with a deterministic earlyonset presenilin 1 mutation (www.dian-info.org), or in individuals who are homozygous for the APOE 34 allele (Reiman et al., 2010; Strittmatter and Roses, 1995) . Though laudable and perhaps the only way forward at the present time, these studies have some limitations. Even in large kindreds with deterministic AD-causing mutations, the number of asymptomatic mutation carriers who might be predicted to develop or have preclinical AD within a reasonable time frame is relatively small. Thus, the number of different therapies that might be tested in such a setting will probably be very limited and, because of variance in the age of onset, it is unclear how long such studies would need to extend in order to convincingly demonstrate efficacy. Further, it has been shown that some anti-Ab treatments may have altered efficacy in presenilin mutation carriers (Weggen et al., 2003) .
The 1%-2% of the population that is homozygous for the APOE 34 allele represents another at-risk or preclinical sample Neuron 69, January 27, 2011 ª2011 Elsevier Inc. 207 Neuron Perspective for clinical trials (Reiman et al., 2010) , and being a homozygote increases risk for AD by 15 times compared to APOE 33 or 32 carriers (Farrer et al., 1997; Reiman et al., 2010) . Simple genetic screening could theoretically provide cohorts for selection of trial participants with this geneotype. However, the low frequency of homozygous APOE 34 carriers severely limits their recruitment and possibly even generalizability to the population as a whole.
Choosing such samples as familial early onset AD or people who are homozygous APOE 34 carriers as the intent-to-treat population also raises another issue, which is whether the expected action of the drug is influenced by the genetic makeup of the individuals. For example, presenilin-linked AD is associated with altered Ab42 production (Selkoe, 2001) , while APOE 34 is associated with decreased clearance of Ab from the brain (Holtzman et al., 2000) .
APOE 34 heterozygotes are another at-risk potential sample for prevention trials: these individuals constitute approximately 24%-30% of the population, have three times the risk for AD, about a 10 year lower age-of-onset compared to APOE 33 or 32 carriers (Farrer et al., 1997) , and represent 50% of AD cases (Roses, 1997) . Although they have one-fifth the risk for AD compared to 34 homozygotes, they are more than eight times easier to recruit by virtue of their prevalence. Thus, a prevention trial with heterozygotes may be carried out efficiently and be more generalizable to the majority of AD patients.
In many scenarios, a 15-20 year timeline would be the minimum time to test, possibly retest, and widely deploy an effective true primary prevention therapy or a therapy for the clearly asymptomatic preclinical stages of AD. In the interval, millions of people will continue to develop AD. So what do we do for them? First, we can simply hope that the predictions of the cascade hypothesis are wrong and that trigger-targeting therapy will show better efficacy in current trials than might be predicted. Evidence for efficacy and safety would probably mean much more rapid approval for symptomatic use. Second, we can renew our efforts to identify novel downstream targets and develop novel neuroprotective or regenerative therapies that may be more efficacious than targeting upstream pathways in true treatment trials. These studies would be greatly facilitated by the development of animal models that recapitulate the full disease phenotype.
An important area where the medical and scientific field can improve in order to overcome the treatment versus prevention dilemma is to better align the design of preclinical studies with subsequent clinical trial designs. This means that the usual chronic dosing studies in pre-or early amyloid-depositing APP transgenic mice with anti-Ab therapy must be accompanied or replaced by studies in which the mice have AD-like Ab loads at the time the treatment is initiated. Given that in practice we have not had animal models that recapitulate the entire AD degenerative cascade (Ashe and Zahs, 2010) , there are some practical limitations as to how far one can take this realignment. Thus, we cannot truly evaluate the potential of anti-Ab or neuroprotection therapies to halt neuronal loss because there is such limited neuronal loss in current APP mouse models. Nevertheless, we can at least attempt to be more rigorous and self-critical with respect to the potential clinical translation of preclinical data.
Recognizing and Overcoming the Other Obstacles to Solving the Treatment versus Prevention Dilemma
There are many nonscientific and nonmedical challenges to implementing primary prevention or early intervention in AD. Some of the most challenging aspects are financial in nature; others are regulatory barriers. Financial Obstacles Phase 2 and 3 clinical trials in the pharmaceutical industry overall are inherently complicated, resource-intensive endeavors with high probabilities for failure. Together, phase 2 and 3 programs consume 48% of the costs for each drug launched and may cost on average $185 million and $235 million, respectively (Paul et al., 2010) . Commercially sponsored AD therapeutic programs and most prevention trials are typically more expensive. It is difficult to source the costs of an AD prevention trial for industry as only one such trial has been sponsored: a Ginkgo biloba extract study in France involving about 2800 patients over 5 years (Vellas et al., 2006b) .
The National Institutes of Health has funded several prevention trials including Women's Health Initiative-Memory Study (WHIMS), the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT), Ginkgo Evaluation of Memory Study (GEM) and PreAdvise (Craig et al., 2005; Kryscio et al., 2004; Martin et al., 2002; Snitz et al., 2009 ). These trials were designed in a manner that cost significantly less than current industry-funded treatment trials (Table 1) . For example, some of the studies enhanced the likelihood for AD by choosing participants who were at higher risk or who already had MCI, outcomes were onset of AD or MCI, they had relatively short follow up periods of 4 to 7 years, and they did not incorporate the comprehensive biomarker or imaging assessments that are available today. This enabled recruitment of 2500 to 4500 participants. Based on publicly listed sources (http://www.projectreporter.nih.gov/ reporter.cfm), the comparably large ADAPT (Lyketsos et al., 2007) and GEM Ginkgo biloba extract study (DeKosky et al., 2008) studies have respectively received approximately $44 million and $28 million of total funding. Total costs for these studies are likely higher as they typically leverage infrastructure within the National Institutes of Health and participating academic institutions. Taken together, it is reasonable to estimate that a federally-sponsored prevention trial would cost around U.S. $80-100 million for a 5 year U.S. study. Given this fiscal reality, we must explore ways to run well-powered primary prevention or early intervention studies that do not cost substantially more or even cost less. However, this will be challenging as biomarkers, imaging, or both will probably be needed to both select and stratify the sample population.
In reality, these aforementioned trials were not exclusively primary prevention trials, with varying mixtures of enrolled participants ranging from subjects without AD pathology to others with varying degrees of preclinical AD pathology and others with MCI. Given that these trials largely lacked ancillary biomarker and imaging studies, one can speculate that the trial participants who developed significant symptoms of AD in the first few years of such trials probably had significant AD pathology at the time of enrollment. Without a biomarker-and imaging-based stratification, mixed disease status at enrollment will complicate trial design by creating uncertainty regarding group size and length of trial and also potentially confounding results.
Biomarkers and imaging, as discussed more extensively below, are likely to be essential for future prevention trials, perhaps to either exclude (primary prevention) patients with prodromal AD or select (secondary prevention) participants at risk for progression to symptomatic AD or for use as a surrogate outcome instead of assessing clinical status, and the costs and complexity will rise. Further, the duration of a primary or secondary prevention trial is far longer than what the commercial sector is generally willing to entertain. Thus, novel prevention trials and cost-sharing models need to be explored that involve public and private sector partnership with shared risks and shared rewards. On a much smaller financial scale, such a cost-sharing model has been successfully implemented with the Alzheimer's Disease Neuroimaging Initiative (ADNI) and the returns have exceeded most investigators' initial hopes, although ADNI is not a clinical trial (http://www.adni-info.org/).
Other financial considerations deal with patents and exclusivity of marketing a new therapy for AD. As noted above, the financial resources required to conduct primary prevention or early intervention trials in AD are going to be substantial, and they are certain to take many years to reach a meaningful result. If patents expire during or shortly after clinical testing, a high probability when conducting primary or secondary prevention studies, and exclusivity is limited or nonexistent, then private sector developers of AD therapies will be reluctant to conduct primary or secondary prevention trials in AD as the return on investment would be limited and not justify the risks. The sufficient return on investment issue is a sensitive one. In our current drug development environment, we need to revisit the legal policies that would discourage investment in primary prevention studies. Such policies need to transparently balance public health needs with private sector marketplace driven incentives. These issues are of course not restricted to AD but germane to our broader efforts to move away from a health care system that is designed to treat the sick, to one that tries to maintain our wellness.
Regulatory Considerations
Coupled with these financial obstacles are regulatory and methodological obstacles that deal with acceptable trial design. Current Food and Drug Administration regulatory guidelines for AD require that a drug show benefit for patients with AD dementia on cognition and that clinical benefit be demonstrated either by global or staging assessment or in activities of daily living (ADL). For example, nearly all 18-month-long trials for mild or for mild to moderate AD used the ADAS-cog as the cognitive measure and the Clinical Dementia Rating or an ADL scale for the test for clinical significance (Schneider and Sano, 2009 ). The trials that tested cholinesterase inhibitors for mild cognitive impairment used the onset of AD dementia as the primary outcome supported by required improvement on a cognitive test (Raschetti et al., 2007) . If such cognitive and functional measures are required in the design of primary or secondary prevention trials, they will probably require nearly 10 or more years to conduct. To adequately power such a study will be challenging and add significant and possibly insurmountable costs. From a regulatory point of view, a primary prevention trial would be done to support an indication or label such as, ''drug X is indicated for the treatment of patients at risk for AD (or have preclinical AD) to delay the onset of prodromal AD or attenuate the course of cognitive impairment.'' Such an indication would break new ground as it would define a particular at-risk state defined by biomarkers and outcomes that fall short of currently recognized clinical states or diagnoses such as AD dementia. This requires, however, that the at-risk state or marker be recognized and validated as defining the target population for the drug and that the outcomes of cognitive change or onset of a subtle clinical state such as mild cognitive impairment be accepted as legitimate outcomes by regulators.
For early phase prevention trials, changes in the nonclinical endpoints can be reasonably accepted if the change is predictive of a clinical outcome. For AD, however, this would require demonstration that, for example, reductions in brain amyloid tracer due to an experimental drug are associated with subsequent attenuation of cognitive decline or improved quality of life. At present, it is uncertain whether current AD biomarkers can be used as surrogates for clinical measures. Indeed, at this point the field is trapped by a conundrum; we would like to use biomarkers as surrogates in clinical trials, but we have yet to definitively establish the link between the surrogate marker with cognitive or functional endpoints.
Next Steps: How Do We Collectively Ensure that Novel Therapies Are Tested in the Appropriate Populations? A largely unspoken concern among many is that AD therapies in development will demonstrate efficacy against the target or biomarker (e.g., lower Ab levels, clear Ab deposits from the brain), meet the ''safe enough'' requirement, yet fail to show clinical efficacy in clinical trials. Because of economic and regulatory forces, such clinical failures will result in the termination of development of the drug. But, if tested in a primary prevention or early intervention trial, the therapy might show remarkable efficacy. Clearly, no one wants this very plausible hypothetical situation to become reality. In order to prevent this from happening we outline some of the key next steps.
First, we must continue the funding of studies that are needed to prove biomarkers can be used as endpoints and represent truly valid clinical surrogate endpoints. Given the cost and risks associated with developing drugs for prevention of AD, it is likely that the development process will need to be staged and all phases of the approach linked to biomarkers. In the first stage, premorbid biomarkers for the pathology of AD would be used to select patients or enrich a sample for likelihood of progression to AD in a reasonable time-frame. Examples of premorbid biomarkers for primary prevention studies might be those based on APOE genotype alone or more extended genotypes that might emerge from ongoing genome-wide association studies. For secondary prevention studies, one might consider diagnostic biomarkers such as CSF Ab, tau, or both or imaging studies such as FDG-PET profile, brain amyloid load, or hippocampal or medial temporal lobe volume. In either case, more than one biomarker may be needed to better identify an asymptomatic risk state or preclinical AD that is currently defined only as a biomarker positive risk state. In the second stage, biomarkers will be needed to demonstrate that the therapy is appropriately modifying the target. For example, with an anti-Ab antibody-based therapy, a decrease in brain amyloid tracer retention with an Ab antibody therapy would indicate target engagement and thereby justify further trials. In the third stage, biomarkers might be used as surrogate endpoints. In a primary prevention trial, the endpoint might be time to conversion to a stage 1 biomarker or, for a secondary prevention trial, time to conversion of a stage 2 biomarker. Although biomarker-based trials can add substantial costs on a per subject basis to the trial, these costs might be offset partially or wholly by possible reductions in length of trial, reductions in sample size needed, or both. Development of plasma-based biomarkers that predict preclinical stages of AD could considerably reduce the cost of a biomarker-based prevention trial, making it much more feasible from an economic point of view. However, despite intensive efforts, even state-dependent diagnostic plasma biomarkers that reliably distinguish AD patients from controls have yet to be developed. In any case, the knowledge-based, regulatory, and legal issues involved in using both validated and novel surrogate biomarkers for AD trials are substantial and require detailed consideration (Katz, 2004) .
A biomarker-based approach to AD prevention or early intervention trials will probably increase the costs associated with the trial and is not without inherent risk. Even if the regulatory agencies give initial approval of a therapy based on biomarker outcomes, there would have to be long-term postapproval efficacy studies (phase 4) that track whether the biomarker effect led to delay of cognitive impairment and dementia. Only this type of morbidity data will provide the evidence base for continued use of the therapy.
Second, we must find ways to ensure that the commercial sector will invest in prevention trials even if they take 10 or more years to complete. With huge investments already made by the commercial sector in novel AD therapeutics, it will not take too many additional negative trials for the pharmaceutical industry to significantly reduce their investment in novel AD therapeutics. To ensure that we have the best possible therapies moving forward, we cannot afford to have the commercial sector largely abandon their efforts to develop novel AD therapeutics. The recent history of stroke therapeutics is highly informative in this regard. As highlighted in a recent review (O'Collins et al., 2006) , out of 114 novel treatments tested in humans for stroke, only tissue plasminogen activator demonstrated sufficient efficacy and safety in human studies to be approved by the Food and Drug Administration. Because of this poor record of translation, efforts to develop novel stroke therapies have been severely curtailed in the commercial sector. The net effect of these negative trials is that the chances of developing novel breakthrough stroke therapies in the foreseeable future have been significantly reduced. The authors of that review on stroke therapeutics make several conclusions that are highly relevant to the AD field regarding alignment of preclinical studies and human clinical trials design. They suggest that some of the underlying factors that may have led to the high failure rate of stroke drugs are (1) limited preclinical assessment of many stroke therapies prior to human testing, (2) lack of alignment between the preclinical studies and the human trials and (3) overall lack of concordance between efficacy observed in preclinical models and clinical trial outcomes.
As compared to stroke, where defining a homogenous intentto-treat population is extremely challenging, in AD we may have the tools to identify a well-defined population with respect to AD-related pathology or lack thereof and also the capability to design preclinical studies that might more closely match the pathological state of those enrolled in the trial, at least with respect to amyloid burdens for anti-Ab therapies. Thus, a third key step moving forward is to ensure that these kinds of alignments, when feasible, occur for investigative new drug approvals. By insisting that preclinical data and clinical trial design are aligned, the likelihood of translational success in novel AD therapeutics might be increased.
Given the recent advances in the AD field, it is reasonable to believe that many of the medical and scientific advances necessary to conduct prevention studies will be overcome. The nonmedical challenges that may prove more difficult to overcome are those regarding the financial underpinnings of prevention or early intervention trials. At present there is no clear road map regarding how such trials might be financially underwritten and who receives the financial rewards if a therapy is shown to have benefit. Moreover, if the scientific and medical advances result in trial designs that are substantially more expensive, rather than less expensive, then the financial obstacles will become greater. Because there is no clear path forward at this time, a fourth step is to make certain the issues of who pays and who gets rewarded are openly discussed. Indeed, all the stake holders need to recognize that this may be a critical issue to address, not only for AD prevention trials but prevention trials for many neurodegenerative conditions. Ultimately, addressing this obstacle may require revisiting patent law and laws or guidelines regarding market exclusivity.
A recent report estimated that the current annual worldwide costs of care for those with AD is approximately 1% of the world's GDP (U.S. $600 billion/year; Alzheimer's Disease International, 2010). Given the enormous economic burden, there is an overriding imperative to transcend the obstacles to conducting the most appropriate trials that will have the greatest potential impact on the disease for any given novel therapeutic. If we can gain the scientifically based consensus among the many stakeholders, then we can collectively develop a road map that addresses the obstacles highlighted in this review that block conducting the necessary preventative studies. This road map will be complex in its formulation as it will need to not only involve physicians, researchers, and patients and their caregivers but also the commercial sector, foundations, drug approval agencies, legislators, and governments, and be expensive to implement. However, it is a challenge that we must face and overcome.
